Latest news

On «Grindeks» Financial Results in 2009
26.02.2010
Today, on 26 February, JSC «Grindeks» has submitted the non-audited consolidated financial statements on 2009 to "NASDAQ OMX Riga". Non-audited financial results confirm that the turnover of the «Grindeks» Group amounted to 53.6 million lats in 2009, which is by 8.5 million lats or 13.7% less than in 2008. In its turn, net profit related to the shareholders of the holding company, amounted to 3.7 million lats in the accounting period, which is by 58.9% less in comparison with 2008.

JSC «Grindeks» signs agreement with Investment and Development Agency of Latvia on co-financing of 2.8 million lats from ERDF
26.02.2010
JSC «Grindeks» informs that today, on 26 February, the company has signed an agreement with Investment and Development Agency of Latvia on co-financing of 2.8 million lats from the European Regional Development Fund (ERDF) for construction of Ursodeoxycholic acid (UDCA) manufacturing unit.

JSC «Grindeks» informs on publication in information portal BNS
15.02.2010
Research and development of new products is one of the priorities of JSC «Grindeks» - every year «Grindeks» reviews different versions of new medications in cooperation with the leading Latvian and international research organizations.

JSC «Grindeks» received approval of co-financing from ERDF for construction of UDCA manufacturing unit
12.02.2010
JSC «Grindeks» informs that it has received approval from the government agency “Investment and Development Agency of Latvia” of allocation of the co-financing from the European Regional Development Fund for the construction of UDCA (ursodeoxycholic acid) manufacturing unit. Allocated amount of co-financing is 2.8 million lats.

Clinical trial on Mildronate® is successfully finished
03.02.2010
JSC «Grindeks» informs that it has successfully finished the clinical trial on the influence of the brand product Mildronate® on the treatment of angina.

Laila Klavina